Heart conditions come in many forms, affecting individuals of all ages and backgrounds. Yet often, treatments have taken a one-size-fits-all approach, with a few commonly used medicines prescribed to manage symptoms. Tenaya is 100% committed to discovering and developing new medicines for heart conditions. We hope to not just alleviate symptoms, but to change the course of disease by targeting its
underlying genetic causes. Founded by leading researchers specializing in genetic medicines, rare diseases and the biology of the heart, Tenaya built specialized capabilities to translate our scientific insights into new treatments. We are currently advancing a pipeline of investigational therapeutics with the potential to transform and extend the lives of patients. Tenaya was founded by leading cardiovascular scientists and we work to incorporate the patient community voice in everything we do. Wendy Borsari, our Associate Director of Patient Advocacy, lives with hypertrophic cardiomyopathy (HCM). We also formed a Patient Advisory Council (PAC) of community members with cardiomyopathies in 2022 so that we could learn directly from people with these conditions early and often. We meet with this group of 12 individuals regularly to obtain input on study design, educational materials, and unmet needs of the patient community. This page is sponsored by Tenaya Therapeutics. Please note that certain content on our page is intended for U.S. Tenaya’s gene therapies are investigational and have not been approved by the U.S. Food and Drug Administration (FDA) or any other countries’ health authority or regulatory agency.
